CHD/Prevention

Top Story

2 decades of pharmacological prevention

2 decades of pharmacological prevention
August 17, 2017

In 1950, Konrad Bloch, a refugee from Nazi Germany, elucidated the cholesterol synthetic pathway. Thirty-seven years later, lovastatin, the first inhibitor of HMG-CoA reductase — the principal rate-limiting enzyme for cholesterol synthesis — was approved by the FDA for clinical use. This class of drugs, statins, has revolutionized the pharmacological prevention of CVD.

In the Journals Plus

Cardiovascular prognosis poor with type 1 diabetes, incident stroke

August 16, 2017
Adults with type 1 diabetes and incident stroke are at risk for all-cause mortality and have a poor cardiovascular prognosis, especially if they experience hemorrhagic…
In the Journals

Depression after CAD diagnosis may increase risk for death

August 15, 2017
Patients who were diagnosed with depression at any time after a CAD diagnosis had a twofold increased risk for death, according to a study published in European Heart
In the JournalsPerspective

CHD risk higher in obesity without metabolic syndrome

August 15, 2017
Patients who are overweight or obese with healthy cholesterol levels and BPs have a higher risk for CHD compared with those at a healthy weight, according to a…
More Headlines »
CME

Statin Therapy: Assessing Intolerance, Drug Interactions and Use in Renal Insufficiency

This activity is supported by an educational grant from Kowa-Lilly.

Dyslipidemia is a major modifiable risk factor for cardiovascular disease, especially in patients with type 2 diabetes…
More »
Video
Meeting News

VIDEO: IMPACT trial assesses prevention strategies for patients with CVD risk factors

December 4, 2016
More »
Resource Centers
Heart in Diabetes

Heart in Diabetes

Video
Meeting News

VIDEO: Discussion on diabetes drugs, CV outcomes fruitful

July 17, 2017
More »
Advertisement
Advertisement